CLINICAL CHEMISTRY HARR
問題一覧
1
A. Tandem-mass spectroscopy
2
C. Hepatic coma
3
A.
4
C. Hepatic coma can result from Reye’s syndrome
5
D. Stasis of blood in the line caused increased ammonia
6
B. Catabolism of purines
7
A. Renal failure
8
A. Levels above 10 mg/dL cause urinary tract calculi
9
A. Uricase coupled to the Trinder reaction
10
C. The nitrogen content of proteins is constant
11
B. Coordinate bonds between Cu+2 and carbonyl and imine groups of peptide bonds.
12
C. Polypeptides and compounds with repeating imine groups react
13
B. Folin–Lowry
14
A. Total protein and albumin are about 10% higher in ambulatory patients
15
A. Dehydration syndromes
16
A. Multiple myeloma
17
D. Malignancy
18
B. Bromcresol purple (BCP)
19
A. The presence of penicillin
20
A. Negatively, anode
21
B. Ionic strength of the buffer
22
A. Electroendosmosis
23
C. Loss of contact between a buffer chamber and the medium
24
D. IgG
25
D. Transferrin
26
A. High-resolution procedures detect monoclonal and oligoclonal bands at a lower concentration
27
C. Hepatic cirrhosis
28
B. Polyacrylamide gel
29
A. Oil Red O
30
C.
31
A. Myocardial infarction (MI)
32
A. α1-Antitrypsin deficiency
33
C. Serial low levels indicate compromised nutritional status
34
D. Ceruloplasmin
35
A. Hemopexin
36
A. High-performance liquid chromatography
37
C. – C→S→F→A +
38
B. Hgb DPunjab
39
B. HgbLepore
40
B. – F→A→S→C +
41
A. Hgb DPunjab
42
A. Proteins are separated by electrophoresis followed by overlay of monospecific anti-immunoglobulins
43
B. Concave to the protein of greatest molecular weight
44
B. When testing for a monoclonal gammopathy, both serum and urine must be examined
45
A. Oligoclonal banding is seen in the CSF of greater than 90% of multiple sclerosis cases
46
C. CSF should be concentrated 50- to100-fold before performing IFE
47
D. Serum-free light chain immunoassay
48
D. Measurement of serum-free light chains
49
D. Age greater than 60 at the time of monoclonal protein discovery
50
A. A stationary support is not used
51
C. – Chylomicrons →β→pre-β→α +
52
A. Very low-density lipoprotein (VLDL)
53
A. VLDL
54
C. 50%
55
A. Apoprotein A-I
56
C. IDL
57
B. ApoB-100 receptor defect
58
C. Apo-B deficiency
59
A. Hypothyroidism
60
D. Apoprotein A-I deficiency
61
D. There are several subfractions of both HDL and LDL
62
C. Lipid profile, fasting, every 5 years
63
C. 12 hours; nothing but water allowed
64
C. LDL cholesterol
65
B. <40 mg/dL
66
C. Total cholesterol and HDL cholesterol
67
C. Niemann–Pick disease
68
B. CDC modification of van Handel and Zilversmit
69
C. Glycerol kinase
70
C. 4-Aminoantipyrine
71
C. Convert cholesterol esters to free cholesterol
72
D. Ultracentrifugation
73
B. Hydrolyze fatty acids bound to the third carbon atom of cholesterol
74
A. Sulfated cyclodextrin
75
B. All use a detergent to facilitate selective reactivity with reagent enzymes
76
A. Is an independent risk factor for atherosclerosis
77
C. Monounsaturated cis fatty acids
78
B. Perform a direct LDL cholesterol assay
79
A. Total cholesterol and HDL cholesterol
80
C. Converts 1 μmol of substrate to product per minute
81
A. Initial absorbance is measured followed by a second reading after 5 minutes
82
C. The enzyme increases the rate of the reaction
83
D. A competitive inhibitor will alter the apparent Km of the reaction
84
A. Greater than 99 × Km
85
A. Apoenzyme + prosthetic group = holoenzyme
86
enzymatic reactions is true? A. NADH has absorbance maximas at 340 and 366 nm
87
D. Increased production and secretion by cells
88
D. Alcohol dehydrogenase (ADH)
89
B. Amylase
90
B. CK
91
B. The pyruvate-to-lactate reaction proceeds at about twice the rate as the forward reaction
92
A. Pernicious anemia
93
C. Acute appendicitis
94
D. 1:2 or less
95
A. Toxic hepatitis
96
A. Slight hemolysis during sample collection
97
A. Hexokinase and G-6-PD
98
A. Inhibit adenylate kinase
99
C. N-acetylcysteine
100
C. An endogenous competitive inhibitor is present in the serum
HTMLBE
HTMLBE
Yves Laure Pimentel · 64問 · 2年前HTMLBE
HTMLBE
64問 • 2年前PARASITOLOGY
PARASITOLOGY
Yves Laure Pimentel · 111問 · 2年前PARASITOLOGY
PARASITOLOGY
111問 • 2年前other names parasitology
other names parasitology
Yves Laure Pimentel · 70問 · 2年前other names parasitology
other names parasitology
70問 • 2年前CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
Yves Laure Pimentel · 61問 · 2年前CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
61問 • 2年前HISTOPATHOLOGY
HISTOPATHOLOGY
Yves Laure Pimentel · 69問 · 2年前HISTOPATHOLOGY
HISTOPATHOLOGY
69問 • 2年前CC-2 SPECTROPHOTOMETRY
CC-2 SPECTROPHOTOMETRY
Yves Laure Pimentel · 100問 · 2年前CC-2 SPECTROPHOTOMETRY
CC-2 SPECTROPHOTOMETRY
100問 • 2年前CC-3 ELECTROPHORESIS
CC-3 ELECTROPHORESIS
Yves Laure Pimentel · 41問 · 2年前CC-3 ELECTROPHORESIS
CC-3 ELECTROPHORESIS
41問 • 2年前AUBF LAB SAFETY
AUBF LAB SAFETY
Yves Laure Pimentel · 87問 · 2年前AUBF LAB SAFETY
AUBF LAB SAFETY
87問 • 2年前CSF 1
CSF 1
Yves Laure Pimentel · 100問 · 2年前CSF 1
CSF 1
100問 • 2年前CSF 2
CSF 2
Yves Laure Pimentel · 82問 · 2年前CSF 2
CSF 2
82問 • 2年前SEMEN 1
SEMEN 1
Yves Laure Pimentel · 100問 · 2年前SEMEN 1
SEMEN 1
100問 • 2年前SEMEN 2
SEMEN 2
Yves Laure Pimentel · 7問 · 2年前SEMEN 2
SEMEN 2
7問 • 2年前SYNOVIAL FLUID 1
SYNOVIAL FLUID 1
Yves Laure Pimentel · 100問 · 2年前SYNOVIAL FLUID 1
SYNOVIAL FLUID 1
100問 • 2年前SYNOVIAL FLUID 2
SYNOVIAL FLUID 2
Yves Laure Pimentel · 6問 · 2年前SYNOVIAL FLUID 2
SYNOVIAL FLUID 2
6問 • 2年前SEROUS FLUID
SEROUS FLUID
Yves Laure Pimentel · 25問 · 2年前SEROUS FLUID
SEROUS FLUID
25問 • 2年前PLEURAL FLUID
PLEURAL FLUID
Yves Laure Pimentel · 44問 · 2年前PLEURAL FLUID
PLEURAL FLUID
44問 • 2年前PERICARDIAL FLUID
PERICARDIAL FLUID
Yves Laure Pimentel · 18問 · 2年前PERICARDIAL FLUID
PERICARDIAL FLUID
18問 • 2年前PERITONEAL FLUID/ ASCITIC FLUID
PERITONEAL FLUID/ ASCITIC FLUID
Yves Laure Pimentel · 30問 · 2年前PERITONEAL FLUID/ ASCITIC FLUID
PERITONEAL FLUID/ ASCITIC FLUID
30問 • 2年前AMNIOTIC FLUID
AMNIOTIC FLUID
Yves Laure Pimentel · 92問 · 2年前AMNIOTIC FLUID
AMNIOTIC FLUID
92問 • 2年前FECALYSIS
FECALYSIS
Yves Laure Pimentel · 80問 · 2年前FECALYSIS
FECALYSIS
80問 • 2年前OTHER BODY FLUIDS
OTHER BODY FLUIDS
Yves Laure Pimentel · 89問 · 2年前OTHER BODY FLUIDS
OTHER BODY FLUIDS
89問 • 2年前MTLBE- SUHO NOTES
MTLBE- SUHO NOTES
Yves Laure Pimentel · 86問 · 2年前MTLBE- SUHO NOTES
MTLBE- SUHO NOTES
86問 • 2年前MTLBE..
MTLBE..
Yves Laure Pimentel · 35問 · 2年前MTLBE..
MTLBE..
35問 • 2年前CC- CHROMATOGRAPHY
CC- CHROMATOGRAPHY
Yves Laure Pimentel · 19問 · 1年前CC- CHROMATOGRAPHY
CC- CHROMATOGRAPHY
19問 • 1年前CC-OSMOMETRY
CC-OSMOMETRY
Yves Laure Pimentel · 14問 · 1年前CC-OSMOMETRY
CC-OSMOMETRY
14問 • 1年前CC-ELECTROCHEMISTRY TECHNIQUES
CC-ELECTROCHEMISTRY TECHNIQUES
Yves Laure Pimentel · 43問 · 1年前CC-ELECTROCHEMISTRY TECHNIQUES
CC-ELECTROCHEMISTRY TECHNIQUES
43問 • 1年前CC- CARBOHYDRATES
CC- CARBOHYDRATES
Yves Laure Pimentel · 49問 · 2年前CC- CARBOHYDRATES
CC- CARBOHYDRATES
49問 • 2年前CC- DIABETES MELLITUS
CC- DIABETES MELLITUS
Yves Laure Pimentel · 97問 · 2年前CC- DIABETES MELLITUS
CC- DIABETES MELLITUS
97問 • 2年前MAJOR LIPOPROTEINS
MAJOR LIPOPROTEINS
Yves Laure Pimentel · 57問 · 2年前MAJOR LIPOPROTEINS
MAJOR LIPOPROTEINS
57問 • 2年前MINOR LIPOPROTEINS
MINOR LIPOPROTEINS
Yves Laure Pimentel · 63問 · 2年前MINOR LIPOPROTEINS
MINOR LIPOPROTEINS
63問 • 2年前PROTEINS
PROTEINS
Yves Laure Pimentel · 37問 · 2年前PROTEINS
PROTEINS
37問 • 2年前PLASMA PROTEINS 1
PLASMA PROTEINS 1
Yves Laure Pimentel · 91問 · 2年前PLASMA PROTEINS 1
PLASMA PROTEINS 1
91問 • 2年前PLASMA PROTEINS 2 (ALPHA 2 REGION)
PLASMA PROTEINS 2 (ALPHA 2 REGION)
Yves Laure Pimentel · 98問 · 2年前PLASMA PROTEINS 2 (ALPHA 2 REGION)
PLASMA PROTEINS 2 (ALPHA 2 REGION)
98問 • 2年前MISCELLANEOUS PROTEINS
MISCELLANEOUS PROTEINS
Yves Laure Pimentel · 61問 · 2年前MISCELLANEOUS PROTEINS
MISCELLANEOUS PROTEINS
61問 • 2年前Liver Function Test 1
Liver Function Test 1
Yves Laure Pimentel · 100問 · 2年前Liver Function Test 1
Liver Function Test 1
100問 • 2年前Liver Function Test 2
Liver Function Test 2
Yves Laure Pimentel · 96問 · 2年前Liver Function Test 2
Liver Function Test 2
96問 • 2年前TUMOR MARKERS
TUMOR MARKERS
Yves Laure Pimentel · 33問 · 2年前TUMOR MARKERS
TUMOR MARKERS
33問 • 2年前KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
Yves Laure Pimentel · 41問 · 2年前KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
41問 • 2年前GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
Yves Laure Pimentel · 17問 · 2年前GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
17問 • 2年前LIPID STORAGE DISEASES
LIPID STORAGE DISEASES
Yves Laure Pimentel · 14問 · 2年前LIPID STORAGE DISEASES
LIPID STORAGE DISEASES
14問 • 2年前PROTEINS
PROTEINS
Yves Laure Pimentel · 71問 · 2年前PROTEINS
PROTEINS
71問 • 2年前QUICK FIRE- ELECTRODES
QUICK FIRE- ELECTRODES
Yves Laure Pimentel · 7問 · 2年前QUICK FIRE- ELECTRODES
QUICK FIRE- ELECTRODES
7問 • 2年前ELECTROLYTES
ELECTROLYTES
Yves Laure Pimentel · 10問 · 2年前ELECTROLYTES
ELECTROLYTES
10問 • 2年前DRUGS
DRUGS
Yves Laure Pimentel · 27問 · 2年前DRUGS
DRUGS
27問 • 2年前TOXIC AGENTS:
TOXIC AGENTS:
Yves Laure Pimentel · 12問 · 2年前TOXIC AGENTS:
TOXIC AGENTS:
12問 • 2年前HEMATOLOGY 1 (HEMATOPOIESIS 1)
HEMATOLOGY 1 (HEMATOPOIESIS 1)
Yves Laure Pimentel · 100問 · 2年前HEMATOLOGY 1 (HEMATOPOIESIS 1)
HEMATOLOGY 1 (HEMATOPOIESIS 1)
100問 • 2年前HEMATOLOGY (HEMATOPOIESIS 2)
HEMATOLOGY (HEMATOPOIESIS 2)
Yves Laure Pimentel · 29問 · 2年前HEMATOLOGY (HEMATOPOIESIS 2)
HEMATOLOGY (HEMATOPOIESIS 2)
29問 • 2年前hema diseases
hema diseases
Yves Laure Pimentel · 25問 · 2年前hema diseases
hema diseases
25問 • 2年前AML
AML
Yves Laure Pimentel · 43問 · 2年前AML
AML
43問 • 2年前GLOBIN SYNTHESIS
GLOBIN SYNTHESIS
Yves Laure Pimentel · 71問 · 2年前GLOBIN SYNTHESIS
GLOBIN SYNTHESIS
71問 • 2年前HEMATOLOGY REFERENCE RANGES
HEMATOLOGY REFERENCE RANGES
Yves Laure Pimentel · 31問 · 2年前HEMATOLOGY REFERENCE RANGES
HEMATOLOGY REFERENCE RANGES
31問 • 2年前DISORDERS OF PRIMARY HEMOSTASIS
DISORDERS OF PRIMARY HEMOSTASIS
Yves Laure Pimentel · 34問 · 2年前DISORDERS OF PRIMARY HEMOSTASIS
DISORDERS OF PRIMARY HEMOSTASIS
34問 • 2年前PLATELET DISORDERS
PLATELET DISORDERS
Yves Laure Pimentel · 37問 · 2年前PLATELET DISORDERS
PLATELET DISORDERS
37問 • 2年前CHARACTERISTICS OF CLOTTING FACTORS
CHARACTERISTICS OF CLOTTING FACTORS
Yves Laure Pimentel · 100問 · 2年前CHARACTERISTICS OF CLOTTING FACTORS
CHARACTERISTICS OF CLOTTING FACTORS
100問 • 2年前4. CLASSIFICATION OF MACROPHAGE
4. CLASSIFICATION OF MACROPHAGE
Yves Laure Pimentel · 12問 · 2年前4. CLASSIFICATION OF MACROPHAGE
4. CLASSIFICATION OF MACROPHAGE
12問 • 2年前3. NATURAL OR INNATE IMMUNITY
3. NATURAL OR INNATE IMMUNITY
Yves Laure Pimentel · 39問 · 2年前3. NATURAL OR INNATE IMMUNITY
3. NATURAL OR INNATE IMMUNITY
39問 • 2年前5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
Yves Laure Pimentel · 55問 · 2年前5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
55問 • 2年前6. PHAGOCYTOSIS Chemotaxis
6. PHAGOCYTOSIS Chemotaxis
Yves Laure Pimentel · 37問 · 2年前6. PHAGOCYTOSIS Chemotaxis
6. PHAGOCYTOSIS Chemotaxis
37問 • 2年前8. NATURE OF ANTIGEN
8. NATURE OF ANTIGEN
Yves Laure Pimentel · 44問 · 2年前8. NATURE OF ANTIGEN
8. NATURE OF ANTIGEN
44問 • 2年前9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
Yves Laure Pimentel · 50問 · 2年前9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
50問 • 2年前1. HISTORY
1. HISTORY
Yves Laure Pimentel · 69問 · 2年前1. HISTORY
1. HISTORY
69問 • 2年前2. TYPES OF IMMUNITY
2. TYPES OF IMMUNITY
Yves Laure Pimentel · 38問 · 2年前2. TYPES OF IMMUNITY
2. TYPES OF IMMUNITY
38問 • 2年前7. PHAGOCYTOSIS Engulfment and Digestion
7. PHAGOCYTOSIS Engulfment and Digestion
Yves Laure Pimentel · 21問 · 2年前7. PHAGOCYTOSIS Engulfment and Digestion
7. PHAGOCYTOSIS Engulfment and Digestion
21問 • 2年前8. PHAGOCYTOSIS EXOCYTOSIS
8. PHAGOCYTOSIS EXOCYTOSIS
Yves Laure Pimentel · 15問 · 2年前8. PHAGOCYTOSIS EXOCYTOSIS
8. PHAGOCYTOSIS EXOCYTOSIS
15問 • 2年前10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
Yves Laure Pimentel · 32問 · 2年前10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
32問 • 2年前11. TRANSPLANTATION IMMUNOLOGY
11. TRANSPLANTATION IMMUNOLOGY
Yves Laure Pimentel · 30問 · 2年前11. TRANSPLANTATION IMMUNOLOGY
11. TRANSPLANTATION IMMUNOLOGY
30問 • 2年前2. LYMPHOID ORGANS
2. LYMPHOID ORGANS
Yves Laure Pimentel · 38問 · 2年前2. LYMPHOID ORGANS
2. LYMPHOID ORGANS
38問 • 2年前3. CLUSTER OF DIFFERENTIATION
3. CLUSTER OF DIFFERENTIATION
Yves Laure Pimentel · 48問 · 2年前3. CLUSTER OF DIFFERENTIATION
3. CLUSTER OF DIFFERENTIATION
48問 • 2年前4. T-CELL DIFFERENTIATION
4. T-CELL DIFFERENTIATION
Yves Laure Pimentel · 35問 · 2年前4. T-CELL DIFFERENTIATION
4. T-CELL DIFFERENTIATION
35問 • 2年前5. T CELL IMMUNODEFICIENCIES
5. T CELL IMMUNODEFICIENCIES
Yves Laure Pimentel · 18問 · 2年前5. T CELL IMMUNODEFICIENCIES
5. T CELL IMMUNODEFICIENCIES
18問 • 2年前6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
Yves Laure Pimentel · 44問 · 2年前6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
44問 • 2年前7. B CELL IMMUNODEFICIENCIES
7. B CELL IMMUNODEFICIENCIES
Yves Laure Pimentel · 23問 · 2年前7. B CELL IMMUNODEFICIENCIES
7. B CELL IMMUNODEFICIENCIES
23問 • 2年前8. COMBINED T CELL AND B CELL DEFICIENCIES
8. COMBINED T CELL AND B CELL DEFICIENCIES
Yves Laure Pimentel · 34問 · 2年前8. COMBINED T CELL AND B CELL DEFICIENCIES
8. COMBINED T CELL AND B CELL DEFICIENCIES
34問 • 2年前9. COMPARISON OF T AND B CELLS
9. COMPARISON OF T AND B CELLS
Yves Laure Pimentel · 12問 · 2年前9. COMPARISON OF T AND B CELLS
9. COMPARISON OF T AND B CELLS
12問 • 2年前10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
Yves Laure Pimentel · 16問 · 2年前10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
16問 • 2年前11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
Yves Laure Pimentel · 15問 · 2年前11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
15問 • 2年前12. ANTIBODY
12. ANTIBODY
Yves Laure Pimentel · 79問 · 2年前12. ANTIBODY
12. ANTIBODY
79問 • 2年前13. TYPES OF ANTIBODIES
13. TYPES OF ANTIBODIES
Yves Laure Pimentel · 97問 · 2年前13. TYPES OF ANTIBODIES
13. TYPES OF ANTIBODIES
97問 • 2年前14. MONOCLONAL ANTIBODIES
14. MONOCLONAL ANTIBODIES
Yves Laure Pimentel · 11問 · 2年前14. MONOCLONAL ANTIBODIES
14. MONOCLONAL ANTIBODIES
11問 • 2年前1. INTERLEUKINS
1. INTERLEUKINS
Yves Laure Pimentel · 23問 · 2年前1. INTERLEUKINS
1. INTERLEUKINS
23問 • 2年前2. INTERFERONS
2. INTERFERONS
Yves Laure Pimentel · 28問 · 2年前2. INTERFERONS
2. INTERFERONS
28問 • 2年前3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
Yves Laure Pimentel · 8問 · 2年前3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
8問 • 2年前4. COMPLEMENT SYSTEM
4. COMPLEMENT SYSTEM
Yves Laure Pimentel · 19問 · 2年前4. COMPLEMENT SYSTEM
4. COMPLEMENT SYSTEM
19問 • 2年前15. COMPLEMENT SYSTEM
15. COMPLEMENT SYSTEM
Yves Laure Pimentel · 76問 · 2年前15. COMPLEMENT SYSTEM
15. COMPLEMENT SYSTEM
76問 • 2年前16. SYSTEM CONTROLS/COMPLEMENT REGULATION
16. SYSTEM CONTROLS/COMPLEMENT REGULATION
Yves Laure Pimentel · 21問 · 2年前16. SYSTEM CONTROLS/COMPLEMENT REGULATION
16. SYSTEM CONTROLS/COMPLEMENT REGULATION
21問 • 2年前17. COMPLEMENT AND DISEASE STATES
17. COMPLEMENT AND DISEASE STATES
Yves Laure Pimentel · 29問 · 2年前17. COMPLEMENT AND DISEASE STATES
17. COMPLEMENT AND DISEASE STATES
29問 • 2年前18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
Yves Laure Pimentel · 19問 · 2年前18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
19問 • 2年前19. CYTOKINES
19. CYTOKINES
Yves Laure Pimentel · 22問 · 2年前19. CYTOKINES
19. CYTOKINES
22問 • 2年前20. INTERLEUKINS
20. INTERLEUKINS
Yves Laure Pimentel · 24問 · 2年前20. INTERLEUKINS
20. INTERLEUKINS
24問 • 2年前21. INTERFERONS, TNF, TGF, CHEMOKINE
21. INTERFERONS, TNF, TGF, CHEMOKINE
Yves Laure Pimentel · 21問 · 2年前21. INTERFERONS, TNF, TGF, CHEMOKINE
21. INTERFERONS, TNF, TGF, CHEMOKINE
21問 • 2年前1. SERO
1. SERO
Yves Laure Pimentel · 54問 · 2年前1. SERO
1. SERO
54問 • 2年前2. PRECIPITATION
2. PRECIPITATION
Yves Laure Pimentel · 38問 · 2年前2. PRECIPITATION
2. PRECIPITATION
38問 • 2年前3. PASSIVE IMMUNODIFFUSION
3. PASSIVE IMMUNODIFFUSION
Yves Laure Pimentel · 17問 · 2年前3. PASSIVE IMMUNODIFFUSION
3. PASSIVE IMMUNODIFFUSION
17問 • 2年前4. OUCHTERLONY
4. OUCHTERLONY
Yves Laure Pimentel · 15問 · 2年前4. OUCHTERLONY
4. OUCHTERLONY
15問 • 2年前5. ELECTROPHORETIC TECHNIQUE
5. ELECTROPHORETIC TECHNIQUE
Yves Laure Pimentel · 9問 · 2年前5. ELECTROPHORETIC TECHNIQUE
5. ELECTROPHORETIC TECHNIQUE
9問 • 2年前6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
Yves Laure Pimentel · 11問 · 2年前6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
11問 • 2年前7. IMMUNOFIXATION ELECTROPHORESIS
7. IMMUNOFIXATION ELECTROPHORESIS
Yves Laure Pimentel · 29問 · 2年前7. IMMUNOFIXATION ELECTROPHORESIS
7. IMMUNOFIXATION ELECTROPHORESIS
29問 • 2年前問題一覧
1
A. Tandem-mass spectroscopy
2
C. Hepatic coma
3
A.
4
C. Hepatic coma can result from Reye’s syndrome
5
D. Stasis of blood in the line caused increased ammonia
6
B. Catabolism of purines
7
A. Renal failure
8
A. Levels above 10 mg/dL cause urinary tract calculi
9
A. Uricase coupled to the Trinder reaction
10
C. The nitrogen content of proteins is constant
11
B. Coordinate bonds between Cu+2 and carbonyl and imine groups of peptide bonds.
12
C. Polypeptides and compounds with repeating imine groups react
13
B. Folin–Lowry
14
A. Total protein and albumin are about 10% higher in ambulatory patients
15
A. Dehydration syndromes
16
A. Multiple myeloma
17
D. Malignancy
18
B. Bromcresol purple (BCP)
19
A. The presence of penicillin
20
A. Negatively, anode
21
B. Ionic strength of the buffer
22
A. Electroendosmosis
23
C. Loss of contact between a buffer chamber and the medium
24
D. IgG
25
D. Transferrin
26
A. High-resolution procedures detect monoclonal and oligoclonal bands at a lower concentration
27
C. Hepatic cirrhosis
28
B. Polyacrylamide gel
29
A. Oil Red O
30
C.
31
A. Myocardial infarction (MI)
32
A. α1-Antitrypsin deficiency
33
C. Serial low levels indicate compromised nutritional status
34
D. Ceruloplasmin
35
A. Hemopexin
36
A. High-performance liquid chromatography
37
C. – C→S→F→A +
38
B. Hgb DPunjab
39
B. HgbLepore
40
B. – F→A→S→C +
41
A. Hgb DPunjab
42
A. Proteins are separated by electrophoresis followed by overlay of monospecific anti-immunoglobulins
43
B. Concave to the protein of greatest molecular weight
44
B. When testing for a monoclonal gammopathy, both serum and urine must be examined
45
A. Oligoclonal banding is seen in the CSF of greater than 90% of multiple sclerosis cases
46
C. CSF should be concentrated 50- to100-fold before performing IFE
47
D. Serum-free light chain immunoassay
48
D. Measurement of serum-free light chains
49
D. Age greater than 60 at the time of monoclonal protein discovery
50
A. A stationary support is not used
51
C. – Chylomicrons →β→pre-β→α +
52
A. Very low-density lipoprotein (VLDL)
53
A. VLDL
54
C. 50%
55
A. Apoprotein A-I
56
C. IDL
57
B. ApoB-100 receptor defect
58
C. Apo-B deficiency
59
A. Hypothyroidism
60
D. Apoprotein A-I deficiency
61
D. There are several subfractions of both HDL and LDL
62
C. Lipid profile, fasting, every 5 years
63
C. 12 hours; nothing but water allowed
64
C. LDL cholesterol
65
B. <40 mg/dL
66
C. Total cholesterol and HDL cholesterol
67
C. Niemann–Pick disease
68
B. CDC modification of van Handel and Zilversmit
69
C. Glycerol kinase
70
C. 4-Aminoantipyrine
71
C. Convert cholesterol esters to free cholesterol
72
D. Ultracentrifugation
73
B. Hydrolyze fatty acids bound to the third carbon atom of cholesterol
74
A. Sulfated cyclodextrin
75
B. All use a detergent to facilitate selective reactivity with reagent enzymes
76
A. Is an independent risk factor for atherosclerosis
77
C. Monounsaturated cis fatty acids
78
B. Perform a direct LDL cholesterol assay
79
A. Total cholesterol and HDL cholesterol
80
C. Converts 1 μmol of substrate to product per minute
81
A. Initial absorbance is measured followed by a second reading after 5 minutes
82
C. The enzyme increases the rate of the reaction
83
D. A competitive inhibitor will alter the apparent Km of the reaction
84
A. Greater than 99 × Km
85
A. Apoenzyme + prosthetic group = holoenzyme
86
enzymatic reactions is true? A. NADH has absorbance maximas at 340 and 366 nm
87
D. Increased production and secretion by cells
88
D. Alcohol dehydrogenase (ADH)
89
B. Amylase
90
B. CK
91
B. The pyruvate-to-lactate reaction proceeds at about twice the rate as the forward reaction
92
A. Pernicious anemia
93
C. Acute appendicitis
94
D. 1:2 or less
95
A. Toxic hepatitis
96
A. Slight hemolysis during sample collection
97
A. Hexokinase and G-6-PD
98
A. Inhibit adenylate kinase
99
C. N-acetylcysteine
100
C. An endogenous competitive inhibitor is present in the serum